Prospective Grant of Exclusive License: Use of Licensed Patent Rights for Development of Therapies for Prostatic Diseases, 64232 [E7-22303]

Download as PDF 64232 Federal Register / Vol. 72, No. 220 / Thursday, November 15, 2007 / Notices Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 451– 7337; Facsimile: (301) 402–0220; E-mail: boodenm@mail.nih.gov. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Use of Licensed Patent Rights for Development of Therapies for Prostatic Diseases National Institutes of Health, Public Health Service, HHS. ACTION: Notice. pwalker on PROD1PC71 with NOTICES AGENCY: SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied the following patents or patent applications U.S. Patent No. 6,946,133 issued September 20, 2005 and U.S. Patent Application No. 11/ 606,929 filed December 1, 2006, as well as all continuations, divisionals, and issued and pending foreign counterparts [HHS Ref. No E–062–1996/0]; U.S. Patent Application Nos. 60/334,669 and 10/497,003 filed November 30, 2001 and August 24, 2004 respectively, as well as all continuations, divisionals, and issued and pending foreign counterparts [HHS Ref. No. E–124–2001/0, 1]; and U.S. Patent No. 6,165,460 issued December 26, 2000 and U.S. Patent Application No. 09/693,121 filed October 20, 2000; as well as all continuations, divisionals, and issued and pending foreign counterparts [HHS Ref. No E–200–1990/4] to BN ImmunoTherapeutics, which is located in Mountain View, CA. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide and the field of use may be limited to the use of Licensed Patent Rights for development of therapies for prostatic diseases. For the avoidance of doubt, said delivery formulation specifically excludes canary poxvirus vectors, NYVAC, eukaryotic expression vectors, aqueous-based delivery formulations, and recombinant yeast. DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before January 14, 2008 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Michelle A. Booden, PhD., Technology Licensing Specialist, VerDate Aug<31>2005 19:50 Nov 14, 2007 Jkt 214001 The present invention relates to isolated peptides comprising immunogenic peptides derived from PSA. These immunogenic peptides are considered agonist epitopes of the wild-type PSA– 3 cytotoxic T lymphocyte (CTL) epitope, which is an agonist epitope modified from the wild type epitope and shows greater immune stimulating characteristics. This invention claims the physical composition and use of the PSA–3 agonist epitopes, including peptide, nucleic acid, pharmaceutical composition, and method of treatment. The PSA–3 agonist epitopes would have application in a number of traditional and non-traditional vaccine delivery systems for the treatment of cancer. The invention also describes the use of at least one target antigen or immunological epitope as an immunogen or vaccine in conjunction with various costimulatory molecules. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. SUPPLEMENTARY INFORMATION: Dated: November 7, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7–22303 Filed 11–14–07; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Proposed Collection; Comment Request In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 concerning opportunity for public comment on proposed collections of information, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the information collection plans, call the SAMHSA Reports Clearance Officer on (240) 276– 1243. Comments are invited on: (a) Whether the proposed collections of information are necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Proposed Project: Evaluating Cultural Competence in Behavioral Healthcare Education and Training—NEW SAMHSA’s Center for Mental Health Services (CMHS) is soliciting comments concerning its request for approval of a new information collection from graduates of behavioral healthcare education and training programs. The Evaluating Cultural Competence in Behavioral Healthcare Education and Training Interview Guide for Faculty and Administrators (the Faculty/ Administrator Interview Guide) and the Evaluating Cultural Competence in Behavioral Healthcare Education and Training Interview Guide for Graduates (the Graduate Interview Guide) will be used by CMHS to investigate faculty’s, administrators’, and graduates’ perceptions of effectiveness of program curricula to prepare them to function as culturally competent behavioral healthcare providers. In achieving these results, this project will aid CMHS’s effort to further the development of a more culturally competent workforce; thereby enhancing progress toward E:\FR\FM\15NON1.SGM 15NON1

Agencies

[Federal Register Volume 72, Number 220 (Thursday, November 15, 2007)]
[Notices]
[Page 64232]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-22303]



[[Page 64232]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Use of Licensed Patent 
Rights for Development of Therapies for Prostatic Diseases

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive patent license to practice the inventions embodied the 
following patents or patent applications U.S. Patent No. 6,946,133 
issued September 20, 2005 and U.S. Patent Application No. 11/606,929 
filed December 1, 2006, as well as all continuations, divisionals, and 
issued and pending foreign counterparts [HHS Ref. No E-062-1996/0]; 
U.S. Patent Application Nos. 60/334,669 and 10/497,003 filed November 
30, 2001 and August 24, 2004 respectively, as well as all 
continuations, divisionals, and issued and pending foreign counterparts 
[HHS Ref. No. E-124-2001/0, 1]; and U.S. Patent No. 6,165,460 issued 
December 26, 2000 and U.S. Patent Application No. 09/693,121 filed 
October 20, 2000; as well as all continuations, divisionals, and issued 
and pending foreign counterparts [HHS Ref. No E-200-1990/4] to BN 
ImmunoTherapeutics, which is located in Mountain View, CA. The patent 
rights in these inventions have been assigned to the United States of 
America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to the use of Licensed Patent Rights 
for development of therapies for prostatic diseases. For the avoidance 
of doubt, said delivery formulation specifically excludes canary 
poxvirus vectors, NYVAC, eukaryotic expression vectors, aqueous-based 
delivery formulations, and recombinant yeast.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
January 14, 2008 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Michelle A. Booden, PhD., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; Telephone: (301) 451-7337; Facsimile: (301) 402-0220; E-
mail: boodenm@mail.nih.gov.

SUPPLEMENTARY INFORMATION: The present invention relates to isolated 
peptides comprising immunogenic peptides derived from PSA. These 
immunogenic peptides are considered agonist epitopes of the wild-type 
PSA-3 cytotoxic T lymphocyte (CTL) epitope, which is an agonist epitope 
modified from the wild type epitope and shows greater immune 
stimulating characteristics. This invention claims the physical 
composition and use of the PSA-3 agonist epitopes, including peptide, 
nucleic acid, pharmaceutical composition, and method of treatment. The 
PSA-3 agonist epitopes would have application in a number of 
traditional and non-traditional vaccine delivery systems for the 
treatment of cancer. The invention also describes the use of at least 
one target antigen or immunological epitope as an immunogen or vaccine 
in conjunction with various costimulatory molecules.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: November 7, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E7-22303 Filed 11-14-07; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.